Monitoring of neoadjuvant chemotherapy using multiparametric, 23Na sodium MR,and multimodality (PET/CT/MRI) imaging in locally advanced breast cancer |
| |
| Authors: | Michael?A.?Jacobs mailto:mikej@mri.jhu.edu" title=" mikej@mri.jhu.edu" itemprop=" email" data-track=" click" data-track-action=" Email author" data-track-label=" " >Email author,Ronald?Ouwerkerk,Antonio?C.?Wolff,Edward?Gabrielson,Hind?Warzecha,Stacie?Jeter,David?A.?Bluemke,Richard?Wahl,Vered?Stearns |
| |
| Affiliation: | (1) The Russell H. Morgan Department of Radiology and Radiological Science, The Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA;(2) Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA;(3) Department of Radiology and Oncology, The Johns Hopkins University School of Medicine, Traylor Blg, Rm 217, 712 Rutland Ave, Baltimore, MD 21205, USA;(4) Cardiovascular Imaging, NIDDK (National Institute of Diabetes and Digestive and Kidney Diseases), BLDG 10-CRC, RM 3-5340, MSC 1263, 10 Center Drive, Bethesda, MD 20892, USA;(5) Department of Pathology, The Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA;(6) Department of Oncology, The Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA;(7) Radiology and Imaging Sciences, National Institutes of Health Clinical Center, National Institute of Biomedical Imaging and Bioengineering, Bethesda, MD 20892, USA |
| |
| Abstract: | ![]()
We prospectively investigated using advanced magnetic resonance imaging (MRI) and positron emission tomography/computed tomography (PET/CT) to identify radiological biomarkers for treatment response in patients receiving preoperative systemic therapy (PST) for locally advanced breast cancer. Patients with a stage II or III breast cancer receiving PST were selected and underwent positron emission tomography (PET), magnetic resonance imaging (MRI), and breast biopsies at baseline and after the first cycle of PST (days 7–8) during the full course of treatment. PET/CT was acquired after injection of 2-deoxy-2-[18F]-fluoro-d-glucose (18FDG, 0.22 mCi/kg) and quantified with standardized uptake value assessment (SUV). Diagnostic breast MRI and sodium (23Na) was acquired at 1.5 T. Total tissue sodium concentration (TSC), response criteria in solid tumors (RECIST), and volumes were quantified. Treatment response was determined by pathological assessment at surgery. Immunohistochemistry values of the proliferative index (Ki-67) were performed on biopsy specimens. Six of nineteen eligible women (43 ± 11 years) who received PST underwent radiological imaging of 18FDG-PET/CT and MRI for at least two cycles of treatment. Five patients had a pathological partial response (pPR) and one had pathological non-response (pNR). TSC decreased 21% in responders with increases in the non-responder (P = 0.03). Greater reduction in SUV was observed in responders (38%) compared to the non-responder (22%; P = 0.03). MRI volumes decreased after cycle 1 by 42% (responders) and 35% (non-responder; P = 0.11). Proliferation index Ki-67 declined in responders in the first cycle (median = 47%, range = 29–20%), but increased (4%) in the non-responder. Significant decreases in TSC, SUV, and Ki-67 were observed in responders with increases in TSC and Ki-67 in non-responders. Our results demonstrate the feasibility of using multi-modality proton, 23Na MRI, and PET/CT metrics as radiological biomarkers for monitoring response to PST in patients with operable breast cancer. |
| |
| Keywords: | |
| 本文献已被 PubMed SpringerLink 等数据库收录！ |
|
